Search

Search Results

• 

  Anticoagulation in obese patients: challenges and strategies

  Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia

  18-09-2025

  https://doi.org/10.4081/btvb.2025.174

  1856

  PDF: 273

  HTML: 199

  XML: 84
• 

  The key to fibrinolysis and thrombolysis

  Roger Lijnen, Désiré Collen

  09-09-2025

  https://doi.org/10.4081/btvb.2025.368

  1511

  PDF: 276

  HTML: 128

• PO53 | Effectiveness and safety of DOACS in patients with renal transplantation A. Ierardi, A. Strangio, M. Leotta, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU Renato Dulbecco, Catanzaro, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.322

  492

  PDF: 0
• 

  Pharmacokinetic interactions between anticancer drugs and direct oral anticoagulants: clinical implications for safe anticoagulation

  Tzu-Fei Wang, Kristen M. Sanfilippo, Marc Carrier

  16-04-2026

  https://doi.org/10.4081/btvb.2026.434

  107

  PDF: 44

• PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo¹, E. De Bon², L. Scarano¹, R. Fabris¹, E. Pierobon³, S. Barbar² | ¹Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; ²Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; ³Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.339

  504

  PDF: 0

• PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce^1,2, C. Santoro¹, E. Baldacci¹, S. Ligia¹, R. Mormile¹, M. Biglietto¹, M. Totaro¹, F. R. Mauro¹, M. Breccia¹, A. Chistolini¹ | ¹Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; ²Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.313

  502

  PDF: 0
• 

  PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION T.A. Adeyemo, S. Greenley, F. Ware, W. Jones, A. Maraveyas, F. Haque | ¹Centre of Excellence for Data Science, Artificial Intelligence and Modelling DAIM, Faculty of Science and Engineering, University of Hull, UK; ²Hull York Medical School, Hull, UK; ³Academic Library Services, University of Hull, UK; ⁴NHS Humber Health Partnership, Hull, UK

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.552

  105

  PDF: 24
• 

  PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami¹, C. Solowiej Singh ¹, M. Dhami ² | ¹Abrazo Internal Medicine Residency; ²Eastern Connecticut Hematology Oncology, Norwich, CT, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.523

  116

  PDF: 24
• 

  PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati^1|2, P. Gomez-Rosas^1|3, C. Ambaglio¹, V. Brusegan¹, O.C. Cretu¹, E. Galimberti¹, F. Zunino¹, L. Barcella¹, J. Harenberg^4|5, A. Falanga^1|2, M. Marchetti^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Ruprecht Karls University of Heidelberg, Heidelberg, Germany; ⁵DOASENSE GmbH, Heidelberg, Germany

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.522

  93

  PDF: 29
• 

  Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers

  Ezio Zanon, Giancarlo Castaman, Augusto Bramante Federici, Maria Elisa Mancuso, Gianfranco Pasut, Alberto Tosetto, Angiola Rocino, Rita Carlotta Santoro

  26-01-2026

  https://doi.org/10.4081/btvb.2026.415

  848

  PDF: 251

  HTML: 60
• 

  Factor XI inhibitors in cancer-associated venous thromboembolism: what’s next?

  Hiranya M. Dave, Mehrie H. Patel, Keith R. McCrae, Alok A. Khorana

  16-04-2026

  https://doi.org/10.4081/btvb.2026.424

  87

  PDF: 51
• 

  Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

  Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz

  16-05-2024

  https://doi.org/10.4081/btvb.2024.118

  1652

  PDF: 895

• PO78 | Acquired hemophilia A as a paraneoplastic syndrome: two cases report on a rare coexistence M. Gagliardi, L. Capone, A. Ciampa | Centro Emostasi, AORN Moscati, Avellino, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.347

  485

  PDF: 0